Apnea Risk Evaluation System (ARES) divested to Watermark Medical

The divestiture of the Apnea Risk Evaluation System (ARESTM) to Watermark Medical achieves important strategic milestones for each company. Watermark became our exclusive U.S. distributor of ARES in 2009 after the ARES clinical validation studies influenced the Center for Medicare Services reimbursement acceptance of home sleep testing. The ease of use of the ARES and accuracy of the auto-scoring software combined with Watermark’s direct sales force resulted in over 100,000 sleep studies being conducted in three years. The divestiture of ARES allows us to shift resources toward commercialization of our new Advanced Sleep products.